M A N A G E M E N T   B A C K G R O U N D E R

For information contact:
Joni Morford, Communicore
714/721-8081
jmorford@communicore.com


ORQUEST, INC.


S. Mitchell Seyedin, Ph.D. - Founder, Chairman of the Board and Chief Scientific 
Officer has extensive business development and general management experience in 
both start-up and large company environments.  He was most recently the co-
founder and Vice President of Research and Development at Metra Biosystems.  
Prior to Metra Biosystems, he was a Director of Research at Collagen Corporation.  
He received his Ph.D. in Biological Chemistry from the University of South 
Carolina and completed his postdoctoral training in Biochemistry at the University 
of California, Berkeley.

Michael Sumner Estes, Ph.D. - President and Chief Executive Officer has over 20 
years in positions of increasing responsibility in the global medical device industry 
developing and establishing high technology businesses in the cardiovascular field.  
He was a Group Vice President of Baxter Healthcare from 1990 to 1996 and served 
eighteen months as President of Baxter Japan.  He began his career with the 
American Hospital Supply Corporation's Edwards Laboratories division eventually 
becoming President of American's Cardiovascular Company.  Dr. Estes received his 
undergraduate training in Biology at the University of Pennsylvania and his M.S. 
and Ph.D. at West Virginia University in Theoretical and Applied Mechanics.

James W. Poser, Ph.D. - Vice President, Research and Development is well known 
for his work in bone chemistry and skeletal metabolism.  Prior to joining Orquest, he 
was the Senior Vice President of Research and Development at Osteotech.  
Previously, he was Director of Research at Intermedics Orthopaedics, Inc. and 
served as Assistant Professor of Medicine at the University of Texas Health Center, 
Principal Scientist and Head of Bone Growth Factor Program at Mitral Medical 
International, and a research scientist at Procter and Gamble.  He received his Ph.D. 
in Chemistry from the University of California San Diego.

Steven R. Carlson - Vice President, Marketing, Sales and Operations  was formerly 
the Senior Vice President of Marketing at Allergan.  Mr. Carlson worked with 
Allergan for 15 years playing key roles in marketing and strategic planning.  From 
1989 through 1994, he held worldwide responsibility for initiating, developing and 
launching of a neuromuscular product, Botox¨, for Allergan.

James B. Andrews, CPA - Controller founded and operated his own management 
consulting firm from 1988 to 1995.  He assisted public and private corporations 
with their financial management needs, generally in an acting chief financial officer 
or acting controller capacity.  Previously, Mr. Andrews held significant financial 
management positions with three different companies and became a certified public 
accountant while working at Deloitte and Touche. 

Robert Christopher Spiro, Ph.D. - Director of Bone and Cartilage Research came to 
Orquest from Telios Pharmaceuticals in San Diego where he held the position of 
principal scientist and directed the basic research studies of the Decorin 
Proteoglycan project from 1991 to 1994.  Two years prior to this he was a senior 
research associate and assistant member in the Department of Immunology at the 
Scripps Research Institute, La Jolla, CA from 1984 to 1991.  Dr. Spiro received his 
Ph.D. in Immunology from the University of Massachusetts Medical School, 
Worcester MA.

F. Jerry Volenec, Ph.D. - Director of Product Development brings extensive 
experience in the development of drugs, biologics and devices to Orquest.  Most 
recently he worked with Cytel Corporation as their Director of Product 
Development and previously was with Becton Dickinson where he held the position 
of Director of Reagent Product Development.  He also worked with Hana Biologics 
(now Somatix) and with Endotronics in a management capacity.  Prior to his 
industrial experience he was the Director of Development Cell Biology at the School 
of Basic Life Sciences, University of Missouri at Kansas City School of Medicine.  Dr. 
Volenec completed his Doctorate training in Virology and Immunology at Cornell 
University.


Board of Directors

Kenneth W. Anstey has over 25 years of broad experience in the medical device 
industry.  He was formerly the President and CEO of Biofield Corp.  Prior to 
Biofield, he was President and CEO of Mitek Surgical Products, Inc., a medical 
device company developing products for the orthopedic market.  Mitek is now a 
subsidiary of Johnson and Johnson.  Prior to Mitek, he was with Bristol Myers 
Squibb Corporation where he held several senior management positions including 
that of President of Conva Tec and Edward Weck Inc.  Prior to that, he was Vice 
President and Area Manager with American Hospital Supply Corporation.  Mr. 
Anstey has an M.B.A. in Marketing and Finance and a B.A. in Advertising from 
Michigan State University.

Annette M. Bianchi is a General Partner of Weiss Peck & Greer Venture Partners 
and has over 11 years of experience investing in early stage life science companies.  
Prior to Weiss Peck & Greer, she was a general partner at Burr, Egan, Deleage & Co.  
Her areas of expertise include biopharmaceuticals, medical devices, healthcare 
services and medical information systems.  She has also served as a seed investor in 
such companies as Cephalon, CellPro, and HiLife.  She holds a B.S.E. in biomedical 
engineering, magna cum laude, from the University of Pennsylvania and an M.B.A. 
from the Wharton School.

George Dunbar is President and CEO of Metra Biosystems, Inc.  He has 
international business experience in high technology fields including healthcare, life 
sciences/biotechnology, and electronics.  Mr. Dunbar went to Metra Biosystems 
from The Ares-Serono Group, a Swiss healthcare company, where he established a 
licensing, business development, and acquisitions group for their diagnostic and 
pharmaceutical businesses.  Prior to this, Mr. Dunbar served as Vice President of 
Amersham Corporation, Chicago, where he was the General Manager of Amersham 
International's life science business.  He has lived and worked in Europe twice; while 
in the UK, he was General Manager, Eastern Region for Amersham International.  
He also originated and managed the marketing activities for a specialized line of 
medical and industrial radioisotopes for the same company.  He has also worked 
with Motorola's Communications Division.  Mr. Dunbar has a B.S.E.E. and M.B.A. 
from Auburn University.

Russell C. Hirsch, M.D., Ph.D. is a General Partner of Mayfield Fund and joined 
Mayfield in 1991 following more than 9 years of medical and scientific research 
experience.  Mayfield Fund is a leading venture capital firm with interests in health 
care technology and information technology.  Dr. Hirsch currently focuses on 
health care information systems, medical devices, and health care services.  He has 
helped start or finance a number of health care technology companies including 
Tularik, Focal, Millennium Pharmaceuticals and Megabios.  In addition, he is a 
director of Megabios, Neuroperfusion, Araxsys, Inc., Orquest, Intuitive Surgical 
Devices and Vida Healthcare Inc.  He holds an M.D. and Ph.D. in Biochemistry 
from the University of California, San Francisco, and a B.S. in Chemistry from the 
University of Chicago.

Craig C. Taylor has been active in venture capital since 1977 when he joined Asset 
Management Company.  He has Bachelor's and Master's degrees in physics and an 
M.B.A. from Stanford University.  Prior to joining Asset Management Company, he 
worked as a design engineering consultant and in technology licensing at Stanford 
University.  He is a General Partner of Asset Management Associates, AMA 84,  
AMA 89 and AMA 96.  He is a member of the board of directors of Lynx 
Therapeutics, Metra Biosystems, and Pharmacyclics, in addition to several other 
companies.


Scientific Advisory Board

Mark E. Bolander, M.D. is an Associate Professor at the Mayo Medical School, 
Rochester, MN.  His research focuses on extracellular matrix proteins in bone and 
cartilage, regulation of gene expression in fractures by bone growth factors, and the 
treatment of fractures under impaired healing conditions.  He serves on the 
editorial boards of the Journal of Orthopaedic Research, Wound Repair, and 
Regeneration and the Mayo Clinic Proceedings.

David S. Bradford, M.D. is a Professor and Chairman of the Orthopaedic 
Department at the University of California, San Francisco (UCSF) where he is an 
internationally known spine surgeon.  Prior to UCSF, he was Professor, Orthopedic 
Surgery and Chief of Spine Surgery at the University of Minnesota Hospitals in 
Minneapolis.  Dr. Bradford specializes in treating spinal problems and deformities in 
both children and adults, particularly scoliosis.

Joseph A. Buckwalter, M.D. is a Professor of Orthopaedic Surgery at the University 
of Iowa where he specializes in cartilage research biology.  He is Co-Editor-in-Chief 
of the Journal of Orthopaedic Research and consultant Reviewer and Consulting 
Editor for Research of the Journal of Bone and Joint Surgery.  He is on several 
advisory boards dealing with osteoarthritis and rheumatology research.

Thomas A. Einhorn, M.D. is a Professor of Orthopaedics and Director of 
Orthopaedic Research at the Mount Sinai School of Medicine.  His research focuses 
on fracture healing and metabolic bone disease.  He is actively involved in caring for 
patients and designing and implementing clinical trials of growth factors.  He is on 
the Editorial Board of the Journal of Orthopaedic Research, Journal of Bone and 
Mineral Research, and the Journal of the American Academy of Orthopaedic 
Surgeons, and serves as the Associate Editor of the Journal of Bone and Joint 
Surgery.

Herbert Fleisch, M.D. is a Professor of Pathophysiology at the University of Bern, 
Switzerland.  He is a specialist in bone and calcium metabolism with over 200 peer-
reviewed publications, and serves on numerous editorial boards of publications 
related to bone research.  He has served as the Dean of the Medical Facility of the 
University of Bern, and is a past President of the Union of the Swiss Associates for 
Experimental Biology.

Ernst B. Hunziker, M.D. is a Professor of Biomechanics and the Director of the M.E. 
Muller Institute for Biomechanics at the University of Bern, Switzerland.  His areas 
of research and clinical expertise include cartilage, bone growth, and other skeletal 
tissues.  Dr. Hunziker is the Associate Editor of the Journal of Bone and Joint 
Surgery and is a member of the editorial board of Histochemistry.

Joseph M. Lane, M.D. is a Professor at Cornell University Medical College and the 
Director of Orthopedic Laboratory Research and Tissue Engineering at the Hospital 
for Special Surgery in New York.  His extensive research interests comprise collagen 
metabolism and structure, cartilage preservation and transplantation, and metabolic 
diseases including skeletal tumors, connective tissue injury and repair, and bone 
regeneration.


End of document.